← FDA DRUG APPROVALS

FDA ANDA · ANDA214209

SUMATRIPTAN

Sponsor: CIPLA

APPLICATION
ANDA214209
TYPE
ANDA
ORIGINAL APPROVAL
2021-02-22
LATEST ACTION
2026-06-12
ROUTE
NASAL
DOSAGE FORM
SPRAY
MARKETING STATUS
Prescription

Products

SUMATRIPTANPrescription
SUMATRIPTAN 20MG/SPRAY · SPRAY · NASAL

Approval history

2026-06-12Labeling · Supplement 5 · standardAP
2024-06-05Manufacturing (CMC) · Supplement 2 · unknownAP
2021-02-22UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →